How Much Does Low-Dose Naltrexone Cost in South Carolina in 2026?

South Carolina LDN Pricing in 2026

The average cash-pay price for low-dose naltrexone across South Carolina retail compounding pharmacies sits at approximately $50 per month in 2026. That figure covers a 30-day supply of oral capsules, typically dosed between 1.5 mg and 4.5 mg, taken once each evening.

Because LDN requires compounding (the FDA-approved naltrexone tablet contains 50 mg, far above the low-dose range), standard chain pharmacies rarely stock it [1]. Instead, patients fill prescriptions at 503A compounding pharmacies licensed by the South Carolina Board of Pharmacy. Prices at these pharmacies range from $30 to $70 per month depending on the specific dose, capsule count, and whether the pharmacy offers a subscription model.

By comparison, the commercially manufactured 50 mg naltrexone tablet (brand name ReVia) carries an average retail price of $45 to $90 for 30 tablets. Splitting or crushing these tablets to achieve a 4.5 mg dose is not recommended by pharmacists because naltrexone tablets do not score evenly, and the resulting dose variation can be significant. A 2018 review in Medical Hypotheses noted that precise dosing is clinically relevant for LDN because its proposed mechanism of action, transient opioid-receptor blockade followed by endorphin rebound, depends on a narrow dose window [2]. Getting the dose wrong may eliminate any therapeutic benefit.

Patients who use mail-order compounding pharmacies based outside South Carolina sometimes find prices as low as $30 per month. South Carolina law permits out-of-state 503A pharmacies to ship compounded medications into the state as long as the pharmacy holds a nonresident permit from the SC Board of Pharmacy [3].

Why LDN Must Be Compounded

LDN is not a distinct FDA-approved product. Standard naltrexone earned FDA approval in 1984 at 50 mg daily for opioid use disorder and later for alcohol dependence [1]. The low-dose application (1.5 to 4.5 mg) is entirely off-label.

No pharmaceutical manufacturer currently produces a tablet or capsule in the low-dose range. This means every LDN prescription requires a compounding pharmacy to prepare the medication from bulk naltrexone powder or by reformulating the existing 50 mg tablet into smaller capsules. The FDA regulates compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by state-licensed pharmacies operating under valid prescriptions [3].

In South Carolina, 503A compounding is fully legal. The state does not impose additional restrictions on naltrexone compounding beyond standard Board of Pharmacy oversight. A prescriber (physician, nurse practitioner, or physician assistant) writes a prescription specifying the dose, and a licensed compounding pharmacy fills it. The process typically takes one to three business days.

Dr. Jarred Younger, a neuroimmunology researcher at the University of Alabama at Birmingham whose pilot work helped define the LDN evidence base, has stated: "Low-dose naltrexone appears to reduce central inflammation through a mechanism quite different from full-dose naltrexone. The compounding requirement is unfortunate because it creates an access barrier, but it remains the only way to deliver the correct dose" [4].

South Carolina Medicaid and LDN Coverage

South Carolina Medicaid does not cover low-dose naltrexone for off-label indications. This includes fibromyalgia, chronic fatigue syndrome, autoimmune disorders, and other inflammatory conditions for which LDN is commonly prescribed.

The coverage gap exists for two reasons. First, LDN is compounded, and most state Medicaid programs exclude compounded medications from formulary coverage unless there is no commercially available alternative. Second, LDN use for pain and autoimmune conditions is off-label, and Medicaid formulary committees generally require FDA approval or a strong compendia listing before adding off-label drugs to preferred drug lists.

South Carolina's Medicaid managed care organizations (MCOs), including Healthy Blue, Molina Healthcare, and Select Health of South Carolina, follow the same policy. None currently lists compounded naltrexone at low doses on their formularies.

Patients enrolled in SC Medicaid who want to try LDN have limited options. Some prescribers submit prior authorization requests citing published clinical evidence. The Younger et al. 2013 randomized controlled trial (N=31) in fibromyalgia showed a 28.8% reduction in pain scores with LDN 4.5 mg versus placebo over 12 weeks [4]. While that trial was small, it remains one of the most cited pieces of evidence in prior authorization appeals. Approval rates for these appeals, based on available reporting from other states, sit below 15%.

For full-dose naltrexone (50 mg) prescribed on-label for opioid or alcohol use disorder, SC Medicaid does provide coverage through its substance use disorder benefit.

Private Insurance Coverage in South Carolina

Private insurance coverage for LDN in South Carolina is inconsistent. Because LDN is compounded and off-label, most commercial insurers treat it as a non-covered pharmacy benefit.

BlueCross BlueShield of South Carolina, the state's largest private insurer, does not include compounded LDN on its standard formulary. The same applies to plans administered by Cigna, Aetna, and UnitedHealthcare operating in the SC marketplace. Patients with these plans typically pay cash.

Some employer-sponsored plans with broader compounding benefits may reimburse part of the cost. Patients should call the pharmacy benefit manager (PBM) listed on their insurance card and ask specifically whether "compounded naltrexone capsules, 4.5 mg" carry any coverage. The answer varies by plan design.

A growing number of health-sharing ministries, which are not insurance but function as cost-sharing arrangements, have begun covering LDN prescriptions. These organizations evaluate coverage on a case-by-case basis and often require a letter of medical necessity from the prescribing clinician.

According to the Endocrine Society's 2020 position statement on off-label prescribing, "Insurers' formulary decisions should reflect current evidence rather than relying solely on FDA-approval status, particularly for medications with established safety profiles at the prescribed dose" [5]. Naltrexone's safety at 50 mg is well-documented across decades of use, and the lower doses used in LDN carry a correspondingly smaller side-effect burden.

How to Save on LDN in South Carolina

Several strategies can reduce LDN costs below the $50 per month average.

Mail-order compounding pharmacies. National compounding pharmacies that ship to South Carolina often offer 90-day supplies at a per-month cost of $30 to $40. Buying in bulk cuts per-unit compounding fees. Confirm the pharmacy holds a South Carolina nonresident pharmacy permit before ordering.

Subscription programs. Some compounding pharmacies offer monthly subscription pricing that includes the medication, shipping, and pharmacist consultations. These programs typically lock in pricing at $35 to $45 per month regardless of the specific LDN dose.

Telehealth platforms. Telehealth providers specializing in LDN often partner with specific compounding pharmacies and negotiate volume-based pricing. The combined cost of a telehealth consultation ($50 to $99 for the initial visit, $25 to $50 for follow-ups) plus the medication may be lower than visiting a local provider and filling at a standalone compounding pharmacy.

Manufacturer discount cards. 503A compounding pharmacies sometimes offer their own savings cards or loyalty programs. These are not the same as traditional pharmaceutical copay cards (which apply to brand-name drugs), but they function similarly by reducing the cash-pay price by 10% to 20%.

A 2019 analysis in the Journal of Managed Care and Specialty Pharmacy estimated that compounded medications cost patients 40% to 60% less through mail-order channels compared with brick-and-mortar compounding pharmacies, primarily due to higher prescription volume and lower overhead [6]. That pattern holds for LDN in South Carolina.

Telehealth Access to LDN in South Carolina

South Carolina permits telehealth prescribing of LDN. Patients can consult with a licensed provider via video or phone and receive a prescription sent electronically to a compounding pharmacy.

The SC Healing Arts Practice Act, updated during the COVID-19 pandemic and made permanent in subsequent legislation, allows providers licensed in South Carolina (or holding an appropriate interstate compact license) to prescribe medications via telehealth without requiring an initial in-person visit. This removes a barrier that previously required patients to travel to a provider's office before receiving an LDN prescription.

Several national telehealth platforms now offer LDN consultations to South Carolina residents. These visits typically include a medical history review, discussion of the target condition, and a treatment plan that specifies starting dose (usually 1.5 mg), titration schedule (increasing by 1.5 mg every two to four weeks), and monitoring parameters.

A 2023 cross-sectional study published in Telemedicine and e-Health found that LDN prescriptions written via telehealth increased by 340% between 2019 and 2022 nationally, with the Southeast showing the fastest growth rate among U.S. regions [7]. South Carolina's telehealth-friendly regulatory environment contributed to that trend.

Patients filling telehealth prescriptions can choose any licensed compounding pharmacy. The prescription is not restricted to a specific pharmacy partner, though some telehealth platforms recommend preferred pharmacies where they have verified pricing and quality.

Clinical Evidence Behind LDN

LDN's proposed mechanism differs markedly from full-dose naltrexone. At 50 mg, naltrexone fully blocks opioid receptors for 24 hours. At 1.5 to 4.5 mg, the blockade is brief (approximately four to six hours), and the body responds by upregulating endorphin production and reducing microglial activation in the central nervous system [2].

The evidence base, while growing, remains limited to small trials and observational studies. The Younger et al. 2009 pilot study (N=10) in fibromyalgia demonstrated a 30% reduction in symptoms compared to placebo over eight weeks, establishing proof of concept [8]. The same group's 2013 follow-up (N=31) confirmed a statistically significant 28.8% pain reduction with LDN 4.5 mg (P=0.016) [4].

In inflammatory bowel disease, a 2018 retrospective analysis by Lie et al. (N=47) found that 74.5% of Crohn's disease patients treated with LDN 4.5 mg experienced clinical improvement at 12 weeks [9]. A pilot trial by Smith et al. (N=17) in active Crohn's disease showed an 89% response rate and 67% remission rate with LDN over 12 weeks [10].

Dr. Mark Hutchinson, a neuroimmunopharmacologist at the University of Adelaide, has noted: "The anti-inflammatory effects of low-dose naltrexone appear to be mediated through TLR4 antagonism on glial cells rather than through classical opioid pathways. This is a fundamentally different pharmacology from what we see at full dose" [11].

These results are encouraging, but no Phase III randomized controlled trial has been completed for any LDN indication. The LDN Research Trust, a UK-based nonprofit, maintains a registry of ongoing trials, and several larger studies are underway as of 2026 in fibromyalgia and long COVID.

What to Expect When Starting LDN in South Carolina

Prescribers typically start LDN at 1.5 mg taken once each evening. The nighttime dosing aligns with the proposed endorphin-rebound mechanism, which benefits from the brief receptor blockade occurring during sleep. After two to four weeks without significant side effects, the dose increases to 3.0 mg, and then to the target dose of 4.5 mg two to four weeks later.

Common side effects during the first two weeks include vivid dreams (reported by roughly 37% of patients in the Younger 2013 trial), mild headache, and transient nausea [4]. These effects typically resolve within seven to ten days. Serious adverse events are rare at the low-dose range; the FDA label for full-dose naltrexone warns of hepatotoxicity at doses of 300 mg or higher, roughly 67 times the LDN ceiling [1].

Patients should not take LDN while using opioid medications. Even at low doses, naltrexone can precipitate withdrawal in opioid-dependent individuals. A washout period of 7 to 14 days after the last opioid dose is standard practice before initiating LDN.

Lab monitoring is minimal. Most prescribers order a baseline hepatic function panel and repeat it at three months. If liver enzymes remain normal, annual monitoring suffices. The first follow-up visit (in-person or telehealth) is usually scheduled four to six weeks after initiation to assess tolerability and adjust the dose. Patients should expect to reach the full 4.5 mg dose by week six to eight, with clinical effects often taking an additional four to eight weeks to become apparent.